Abstract:Objective To evaluate the inter-bottle variations, stability in consumption and interchangeability of unassayed biochemistry serum controls. Methods Comparison between unassayed serum controls from a domestic "Pretrol?" and an international "Bio-Rad" manufacturer was conducted in department of laboratory, in May 2016, with Roche Cobas 8000, Roche Hitachi 7600 and Siemens 2400 modular analyzer. The inter-bottle variation was determined by monitoring the inter-batch variation of 10 bottles of control samples after eliminating the intra-batch variation from the same bottle. Stability in consumption was determined as the precision after 7 days storage under 2℃ to 8℃ or 30 days of storage under -20 ℃ since reconstitution. The interchangeability was determined as the precisionbetween the controls from different manufacturers for the same test. Results The inter-bottle imprecision of controls from domestic manufacturer for 13 biochemistry tests (CV concentration 1/CV concentration 2) were potassium (0.26％/0.42％), sodium (0.26％/0.21％), phosphorus (0.00％/0.62％), cholesterol (0.56％/0.54％), total protein (0.52％/0.33％), albumin (0.44％/2.00％), alanine aminotransferase (1.72％/0.57％),γ-glutamylaminotransferase (0.52％/0.62％), aspartate aminotransferase (3.10％/1.09％), lactate dehydrogenase (0.76％/0.91％), alkaline phosphatase (1.13％/0.97％), amylase (0.30％/0.39％) and glucose (0.00％/0.40％). The stability in consumption of the controls from the domestic manufacturer (CV concentration 1/CV concentration 2 under 2℃to 8℃storage;CV concentration 1/CV concentration 2 under-20℃ storage) were potassium (1.06％/0.36％; 0.74％/0.48％), sodium (0.49％/0.59％; 0.72％/0.65％), phosphorus (0.95％/0.80％;1.43％/0.84％), cholesterol (1.49％/1.58％;2.17％/1.80％), total protein (0.84％/0.75％; 1.60％/1.68％), albumin (1.33％/2.28％; 1.94％/2.43％), alanine aminotransferase (1.41％/0.51％;3.24％/1.60％) γ-glutamylaminotransferase (1.16％/1.16％; 2.85％/2.49％), aspartate aminotransferase (4.37％/2.14％; 2.99％/1.31％), lactate dehydrogenase (2.70％/2.54％; 3.84％/2.97％), alkaline phosphatase (2.63％/1.96％; 2.31％/2.10％), amylase (0.95％/2.19％; 1.58％/1.38％) and glucose (0.60％/0.48％; 1.41％/1.55％). The Inter-bottle variation and stability in consumption of biochemistry test unassayed controls from the domestic manufacturer were compatible for clinical assay according to the CV％ specification from the Clinical Biochemistry Test Quality Requirement (WS/T 403-2012). The imprecision of the controls from both the domestic and international manufacturers (CVp concentration 1/CVp concentration2;CVq concentration 1/CVq concentration 2) were potassium (0.52％/0.46％; 2.39％/0.47％), sodium (0.30％/0.17％; 0.81％/0.47％), phosphorus (2.72％/1.11％;4.57％/2.07％), cholesterol (0.29％/1.38％;2.94％/1.81％), total protein (0.66％/2.46％;1.85％/2.54％), alkaline phosphatase (2.67％/4.66％;3.58％/8.55％), total bilirubin (5.71％/5.09％; 9.55％/7.41％), albumin (1.10％/2.61％; 4.79％/1.93％), alanine aminotransferase (6.42％/1.25％;5.74％/1.63％), γ-glutamylaminotransferase (2.27％/4.35％; 4.38％/0.74％), aspartate aminotransferase (0.56％/2.84％; 0.91％/2.11％) and lactate dehydrogenase (2.36％/2.47％; 3.10％/1.52％). The interchangeability of serum controls from domestic manufacturer was better than clinical serum samples. Conclusion The unassayed serum biochemistry test controls from domestic manufacturer are suitable for the intra-laboratory quality control and showed a promising compatibility for inter-laboratory quality control usage .

A-051 Validation and Implementation of the Stanbio Beta-Hydroxybutyrate Assay on Roche c502 Analyzer

Development and validation of a multiplexed LC-MS/MS ketone body assay for clinical diagnostics

Enzymatic detection of α-hydroxybutyrate, an important marker of insulin resistance, and comparison with LC-MS/MS detection

Preliminary comparisons between a point-of-care ketometer and reference method using Steller sea lion pup whole blood and plasma

Quantification of Total Ketone Bodies in Biological Matrices Using Stable Isotope-Labeled Internal Standards and RP-UHPLC-MS/MS

Measuring ketone bodies for the monitoring of pathologic and therapeutic ketosis

A-045 Analytical and Clinical Evaluation of A1c Test by HPLC - LifotronicTM H100Plus Analyzer - in a Brazilian Clinical Laboratory

Analytical Performance Evaluation of the GreenCare A1c and Cera-Stat HbA1c Point-Of-Care Testing Assays

A Tool for Automatic Correction of Endogenous Concentrations: Application to BHB Analysis by LC-MS-MS and GC-MS

Evaluation of agreement between a noninvasive method for real-time measurement of critical blood values with a standard point-of-care device

Comparison of Diagnostic Value Between Serum Beta-Hydroxybutyrate and Urine Ketone in Diagnosis of Diabetic Ketosis

Evaluation of Five Routine Glucose Methods on an Olympus AU5400 Analyzer Using the CDC Hexokinase Reference Method

A-095 A New CO2 Assay with Concentrated Reagent Having Superior Onboard Stability on Mindray BS-2800M Analyzer

Accuracy and Reliability of Whole Blood Bilirubin Measurements Using a Roche Blood Gas Analyzer for Neonatal Hyperbilirubinemia Screening and Risk Stratification

Model Based Study on Monitoring Ketone Bodies to Improve Safety in Intensive Insulin Therapy

In vitro β-hydroxybutyrate stability evaluation in femoral blood and vitreous humor for integration into forensic toxicology practices

B-047 Performance Evaluation of Enzymatic HbA1c Assay on Newly Launched Mindray BS-600M Chemistry Analyzer

Simplified quantification of insulin, its synthetic analogs and C-peptide in human plasma by means of LC-HRMS

Validation and method comparison for a point-of-care lateral flow assay measuring equine whole blood insulin concentrations

Development and validation of a novel 7α-hydroxy-4-cholesten-3-one (C4) liquid chromatography tandem mass spectrometry method and its utility to assess pre-analytical stability

The performance evaluation of unassayed biochemistry serum controls